cisplatin + kanglaite + mitomycin

This is a combination regimen consisting of three agents: - **Cisplatin** is a platinum-based chemotherapeutic that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. It is widely used for various solid tumors. - **Kanglaite** is an injectable emulsion derived from Coix seed oil (traditional Chinese medicine), with proposed antitumor and immunomodulatory effects. It has been shown to enhance the efficacy and reduce the toxicity of standard chemotherapy regimens, possibly by modulating immune responses and inhibiting drug resistance pathways. - **Mitomycin** (commonly mitomycin C) is an antineoplastic antibiotic that acts as a bifunctional alkylating agent after activation, causing DNA crosslinking and inhibition of DNA synthesis. The combination has been studied as salvage or adjunctive therapy in advanced cancers such as non-small cell lung cancer (NSCLC) and gastric cancer. Clinical studies suggest that adding Kanglaite to cisplatin/mitomycin regimens may improve response rates, quality of life scores (e.g., Karnofsky Performance Status), and reduce some adverse effects compared to chemotherapy alone[1][2][7]. The mechanism involves direct cytotoxicity from cisplatin/mitomycin plus immunomodulation and possible chemosensitization from Kanglaite[8].